This Issue is a relatively long one, as it’s something of a catch-up for the holiday period. We look at psychedelic drug development news from the likes of MindMed, Gilgamesh and atai as well as news stories concerning the VA and DEA.
We also review and summarise our recent long-read coverage, as well as provide updates to some of those stories.
Featured content in this Issue:
- MindMed Scraps LSD Microdosing Program
- Eagerly Anticipated Ibogaine Study Publishes
- Compass Pathways Announces 3-Year Research Collaboration with Interventional Psychiatry Chain, Greenbrook TMS
- Gilgamesh’s GM-1020 Shows Antidepressant-Like Activity in Mice
- Cybin Shares Topline Data Suggesting Deuterated DMT Candidates Can Be Bridged; IM Route Possible
- atai Shares Morsel of EMP-01 Data in Phase I Readout
- VA Vows to Fund Psychedelic Research
- DEA Establishes Initial 2024 Aggregate Production Quotas for Psychedelics
Companies, organisations and drug candidates mentioned in this Bulletin include: MindMed, MM-120, Stanford, MISTIC, Ambio Life Sciences, Compass Pathways, Greenbrook TMS, Cybin, Gilgamesh Pharmaceuticals, GM-1020, AstraZeneca, AZD6765, rapastinel, Allergan, CYB004, SPL028, Small Pharma, dDMT, atai Life Sciences, R-MDMA, EMP-01, IDEA-1, EmpathBio, Lykos Therapeutics, Beckley Psytech, Tryp Therapeutics, Clarion Clinics, BetterLife Pharma.
This content is for Pα+ Subscribers
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
